Cesare Massone

Prof. Dr. Cesare Massone

Department of Dermatology, Galliera Hospital, Via Volta, 6, 16128 Genoa, Italy
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2008 in Blood
Verified
Journal Article
Open access
PDF file
RWRein Willemze
Rein Willemze
PJPatty M. Jansen
Patty M. Jansen
LCLorenzo Cerroni
Lorenzo Cerroni
EBEmilio Berti
Emilio Berti
MSMarco Santucci
Marco Santucci
CMChris J. L. M. Meijer
Chris J. L. M. Meijer
In the WHO classification, subcutaneous panniculitis-like T-cell lymphoma (SPTL) is defined as a distinct type of T-cell lymphoma with an aggressive clinical behavior. Recent studies suggest that distinction should be made between SPTL with an α/β T-cell phenotype (SPTL-AB) and SPTL with a γδ T-cell phenotype (SPTL-GD), but studies are limited. To better define their clinicopathologic features, immunophenotype, treatment, and survival, 63 SPTL-ABs and 20 SPTL-GDs were studied at a workshop of the EORTC Cutaneous Lymphoma Group. SPTL-ABs were generally confined to the subcutis, had a CD4−, CD8+, CD56−, βF1+ phenotype, were uncommonly associated with a hemophagocytic syndrome (HPS; 17%), and had a favorable prognosis (5-year overall survival [OS]: 82%). SPTL-AB patients without HPS had a significantly better survival than patients with HPS (5-year OS: 91% vs 46%; P < .001). SPTL-GDs often showed (epi)dermal involvement and/or ulceration, a CD4−, CD8−, CD56+/−, βF1− T-cell phenotype, and poor prognosis (5-year OS: 11%), irrespective of the presence of HPS or type of treatment. These results indicate that SPTL-AB and SPTL-GD are distinct entities, and justify that the term SPTL should further be used only for SPTL-AB. SPTL-ABs without associated HPS have an excellent prognosis, and multiagent chemotherapy as first choice of treatment should be questioned.

1 March 2005 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PDF file
AGArmin Gerger
Armin Gerger
SKSilvia Koller
Silvia Koller
TKThomas Kern
Thomas Kern
CMCesare Massone
Cesare Massone
KSKarin Steiger
Karin Steiger
JSJosef Smolle
Josef Smolle
Early detection of melanoma is essential, and still one of the most challenging problems in clinical dermatology. The early diagnosis of melanoma, however, is still rather poor. Reports assessing accuracy in the clinical diagnosis of melanoma show sensitivity values of 65%–80%, depending on the expertise of the dermatologist ( Miller and Ackermann, 1992 x Miller and Ackermann, 1992 Miller, M. and Ackermann, A.B. How accurate are dermatologists in the diagnosis of melanoma? Degree of accuracy and implicants. Arch Dermatol. 1992; 128: 559–560 https://doi.org/10.1001/archderm.128.4.559 Crossref | PubMed | Google Scholar See all References Miller and Ackermann, 1992 ; Wolf et al, 1998 x Wolf et al., 1998 Wolf, I.H., Smolle, J., Soyer, H.P., and Kerl, H. Sensitivity in the clinical diagnosis of malignant melanoma. Melanoma Res. 1998; 8: 425–429 Crossref | PubMed | Scopus (98) | Google Scholar See all References Wolf et al, 1998 ). For improving diagnostic accuracy, epiluminescence microscopy turned out to be an important tool. In a recent systematic review of diagnostic accuracy of epiluminescence microscopy in detecting melanoma, a 10%–27% higher sensitivity than in clinical diagnosis by the naked eye has been reported ( Mayer, 1997 x Mayer, 1997 Mayer, J. Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma. Med J Aust. 1997; 167: 206–210 PubMed | Google Scholar See all References Mayer, 1997 ).

1 October 2005 in Blood
Verified
Journal Article
Closed access
PDF file
KKKazuo Kodama
Kazuo Kodama
CMCesare Massone
Cesare Massone
ACAndreas Chott
Andreas Chott
DMDieter Metze
Dieter Metze
HKHelmut Kerl
Helmut Kerl
LCLorenzo Cerroni
Lorenzo Cerroni
In the new World Health Organization/European Organization for Research and Treatment of Cancer (WHO/EORTC) classification of cutaneous lymphomas, large B-cell lymphomas (LBCLs) are divided into 3 groups: LBCL, leg-type (LBCLLT); follicle center lymphoma, diffuse type (FCLDT); and LBCL, others (LBCLO). We studied a large number of primary cutaneous LBCLs to test the validity of the classification and to identify prognostic factors for these patients. Ninety-three cases of primary cutaneous LBCL were analyzed for clinicopathologic features, expression of several markers including Bcl-2, Bcl-6, MUM-1, and FOX-P1, in situ hybridization for Epstein-Barr virus, and molecular analyses of IGH gene rearrangement and of Borrelia burgdorferi and human herpesvirus 8 DNA. Patients were classified into the following categories: FCLDT, 44 cases; LBCLLT, 40 cases; and LBCLO, 9 cases. Statistical analyses showed that the LBCLLT and FCLDT groups were clearly distinct in terms of clinicopathologic features and survival. The LBCLO group had features in between those of LBCLLT and FCLDT. Our study shows that accurate morphologic and phenotypic analyses allow us to stratify most patients into the prognostically different categories of LBCLLT and FCLDT. The definition of a third category of LBCLO requires further studies to clarify whether these cases indeed show distinct clinicopathologic features. (Blood. 2005;106:2491-2497)

1 June 2004 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
CMCesare Massone
Cesare Massone
ACAndreas Chott
Andreas Chott
DMDieter Metze
Dieter Metze
KKKatrin Kerl
Katrin Kerl
LCLuigi Citarella
Luigi Citarella
LCLorenzo Cerroni
Lorenzo Cerroni
A new group of subcutaneous, natural killer (NK), NK/T-cell, and other cytotoxic T-cell lymphomas of the skin has been recently described, and some have been included as distinct clinicopathologic entities in the classification of hematologic malignancies recently proposed by the World Health Organization. In the European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas, they would be classified either as CD30- large T-cell lymphoma, small/medium pleomorphic T-cell lymphoma, or subcutaneous T-cell lymphoma. Precise clinicopathologic and prognostic features of all of them have not yet been well characterized. We studied retrospectively 81 biopsies from 50 patients with subcutaneous, blastic natural killer (NK), NK/T-cell, or other non–mycosis fungoides cytotoxic T-cell lymphomas of the skin. Clinical, morphologic, phenotypical, and genetic features and data on Epstein-Barr virus association allowed us to classify our cases according to the following 7 categories: a) subcutaneous “panniculitis-like” T-cell lymphoma (SPTCL): 10 cases (estimated 5-year survival: 80%); b) blastic NK-cell lymphoma: 12 cases (estimated 5-year survival: 0%); c) nasal-type extranodal NK/T-cell lymphoma: 5 patients (estimated 5-year survival: 0%); d) epidermotropic CD8+ T-cell lymphoma: 5 cases (estimated 5-year survival: 0%); e) cutaneous γ/δ T-cell lymphoma: 8 cases (estimated 5-year survival: 0%); f) cutaneous α/β pleomorphic T-cell lymphoma: 8 cases (estimated 5-year survival: 0%); and g) cutaneous medium/large pleomorphic T-cell lymphoma, not otherwise specified: 2 cases. Our study shows that these cutaneous lymphomas can be classified according to precise diagnostic categories. With the exception of SPTCL, analysis of follow-up data from our patients showed that these groups of lymphomas are characterized by an aggressive course, regardless of the diagnostic category.

17 July 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
DIDΙmΙtrios Ioannides
DΙmΙtrios Ioannides
EVE. Vakirlis
E. Vakirlis
LKL. Kemeny
L. Kemeny
BMB. Marinovic
B. Marinovic
CMCesare Massone
Cesare Massone
MNM. Neumann
M. Neumann

1 April 2005 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
CMCesare Massone
Cesare Massone
KKKazuo Kodama
Kazuo Kodama
HKHelmut Kerl
Helmut Kerl
LCLorenzo Cerroni
Lorenzo Cerroni
The histologic diagnosis of early mycosis fungoides (MF) is one of the most vexing problems in dermatopathology. We reviewed the histopathologic features of 745 biopsy specimens from 427 patients (male:female = 277:150; median age, 52 years; range, 3-95 years) with early (patch) lesions of MF collected from the lymphoma database of the Department of Dermatology of the Medical University of Graz (Austria). In all patients, the diagnosis was established by clinicopathologic correlation. The most common histopathologic pattern consisted of a band-like or patchy lichenoid infiltrate admixed with coarse bundles of collagen in the superficial dermis. Epidermotropism of lymphocytes was observed in most cases in one or more forms (single lymphocyte epidermotropism, 22%; basilar lymphocytes, 23%; Pautrier's microabscesses, 19%; “haloed” lymphocytes, 40%; disproportionate exocytosis, 17%; pagetoid epidermotropism, 3%). In 4% of cases, epidermotropism was completely missing. Atypical lymphocytes were present only in 9% of cases. Features of interface dermatitis were observed in 59% of cases. Other unusual findings were the presence of necrotic keratinocytes (23%), melanophages (8%), and extravasated erythrocytes (4%). In 28 patients, two or more biopsies taken on the same day at different body sites showed different histopathologic aspects, underlying the protean features of MF even in a single patient at a given time. Our study expands previous observations on histopathologic features of early lesions of MF. Although sometimes the histopathologic features are not diagnostic, they should be considered consistent with MF and do not rule out the diagnosis.